One such approach is using cell cycle checkpoint inhibitors such as WEE1 or Chk1 inhibitors in combination with DNA damaging agents (i.e., platinum) or PARP inhibitors in BRCA1 deficient breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.